Sharon Barrans

Rearrangement of <i>MYC</i> Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab

Sharon Barrans, Simon Crouch, Alex Smith et al. · Journal of Clinical Oncology · 2010 · 549 citations · Full text

Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report

Stuart Lacy, Sharon Barrans, Philip Beer et al. · Blood · 2020 · 481 citations · Full text

Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy

Chulin Sha, Sharon Barrans, Francesco Cucco et al. · Journal of Clinical Oncology · 2018 · 291 citations · Full text

Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma

Sharon Barrans, Ian Carter, Roger G. Owen et al. · Blood · 2002 · 280 citations · Full text

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

Andrew Davies, Thomas Cummin, Sharon Barrans et al. · The Lancet Oncology · 2019 · 260 citations · Full text